Literature DB >> 31054944

Major Depression and Comorbid Diabetes - Findings from the European Group for the Study of Resistant Depression.

Gernot Fugger1, Markus Dold1, Lucie Bartova1, Alexander Kautzky1, Daniel Souery2, Julien Mendlewicz3, Alessandro Serretti4, Joseph Zohar5, Stuart Montgomery6, Richard Frey1, Siegfried Kasper7.   

Abstract

OBJECTIVE: The major aim of this multicenter study of the European Group for the Study of Resistant Depression (GSRD) was to elucidate associations between major depressive disorder (MDD) and comorbid diabetes.
METHODS: Demographic and clinical information of 1410 patients with a primary MDD diagnosis according to DSM-IV were retrieved cross-sectionally between 2012 and 2016. By applying descriptive statistics, analyses of covariance (ANCOVA) and binary logistic regression analyses, a comparison between patient characteristics with and without comorbid diabetes was performed.
RESULTS: The point prevalence rate for comorbid diabetes across MDD patients was 6%. Individuals with MDD + comorbid diabetes were significantly older, heavier, more likely to be inpatient and diagnosed with additional comorbid chronic somatic diseases. In addition, current suicide risk was significantly increased and melancholic features were more likely pronounced. In general, patients in the MDD + diabetes group received a combination therapy with at least one additional antidepressant rather than various other augmentation strategies.
CONCLUSION: Our analyses depict a lower prevalence rate of diabetes in MDD patients than previous studies. However, in light of the prevalence of diabetes in the geographical area of the study, we found an increased risk for individuals with depression compared to the general population. Current suicide risk is markedly elevated and has to be thoroughly assessed in every patient with comorbid diabetes. Depression severity and treatment response remained unaffected by concurrent diabetes in MDD.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Clinical aspects; Comorbidity; Depression; Diabetes; Suicidality

Mesh:

Year:  2019        PMID: 31054944     DOI: 10.1016/j.pnpbp.2019.109638

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  5 in total

1.  Comorbid Chronic Physical Illnesses in Type 1 Diabetes Adolescents: Personal, Caregiver, and Family Functioning.

Authors:  Demivette Gómez-Rivera; Eduardo Cumba-Avilés
Journal:  Salud Conducta Humana       Date:  2021-12-23

2.  Major depressive symptoms in breast cancer patients with ovarian function suppression: a cross-sectional study comparing ovarian ablation and gonadotropin-releasing hormone agonists.

Authors:  Junhan Jiang; Junnan Xu; Li Cai; Li Man; Limin Niu; Juan Hu; Tao Sun; Xinyu Zheng
Journal:  BMC Psychiatry       Date:  2021-12-11       Impact factor: 3.630

3.  Associations of Serum Cytokines, Growth Factors, and High-Sensitivity C-Reactive Protein Levels in Patients with Major Depression with and without Type 2 Diabetes Mellitus: An Explanatory Investigation.

Authors:  Takashi Hoshikawa; Naomichi Okamoto; Tomoya Natsuyama; Rintaro Fujii; Atsuko Ikenouchi; Yuichi Honma; Masaru Harada; Reiji Yoshimura
Journal:  Neuropsychiatr Dis Treat       Date:  2022-02-03       Impact factor: 2.570

4.  The Choice of Either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients With Major Depressive Disorder.

Authors:  Lucie Bartova; Gernot Fugger; Markus Dold; Alexander Kautzky; Marleen Margret Mignon Swoboda; Dan Rujescu; Joseph Zohar; Daniel Souery; Julien Mendlewicz; Stuart Montgomery; Chiara Fabbri; Alessandro Serretti; Siegfried Kasper
Journal:  Int J Neuropsychopharmacol       Date:  2022-02-11       Impact factor: 5.176

5.  Association between fasting blood glucose and thyroid stimulating hormones and suicidal tendency and disease severity in patients with major depressive disorder.

Authors:  Weiting Liu; Zezhen Wu; Min Sun; Shuo Zhang; Juan Yuan; Dan Zhu; Guimimg Yan; Kaijian Hou
Journal:  Bosn J Basic Med Sci       Date:  2022-07-29       Impact factor: 3.759

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.